Advancing Molecular Diagnostics to Personalize Cancer Therapy
NEW YORK, July 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Advancing Molecular Diagnostics to Personalize Cancer Therapy
http://www.reportlinker.com/p0570470/Advancing-Molecular-Diagnostics-to-Personalize-Cancer-Therapy.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic
Introduction
This report analyzes current and potential world markets for key cancer-based molecular diagnostics, including advances in the field. This report forecasts future growth to 2016. Market segments covered include: breast cancer; colon cancer; prostate cancer; non-small cell lung cancer; melanoma; and renal cancer. This report reviews the direction of research, and key issues facing the industry.
Features and benefits
* Identify key innovations in molecular diagnostics for oncology that may compete with those in development at your company.
* Understand the regulatory challenges facing the developers of molecular diagnostics for cancer.
* Understand the challenges that surround successfully commercializing a combined drug-diagnostic product and learn how to overcome them.
* Discover and analyze the key technology platforms being used in the development of novel molecular diagnostics.
* Discover the forecast market size for key segments of the cancer diagnostics market including: breast, colorectal, prostate, lung, and renal cancer.
Highlights
Advances in genomics, proteomics, molecular imaging, and other new technologies are leading to a molecularly based reclassification of malignancy, creating market opportunities for diagnostic companies.
Companion diagnostics - linking drugs with diagnostics - is expected to become the prevailing health care model, offering advantages for both the prescription drug and diagnostics businesses. For diagnostics companies, combining with a successful companion drug can be a powerful driver of sales, especially when required for prescribing a drug.
If government regulatory agencies increase the use of biomarkers and diagnostics in prescribing decisions, it is likely that drug and diagnostics companies will increase their collaboration. New relationships are likely to develop between partners committed to personalized medicine embracing the approach of specialized pharmaceutical firms.
Your key questions answered
* Which of the cancer diagnostic market segments are forecast to grow most rapidly through to 2016 and thus be the most commercially attractive?
* What are the key innovations in molecular diagnostics that are going to drive market growth?
* How can pharma and diagnostic companies work together to successfully develop combined drug and diagnostic products?
* Which companies are developing the most promising technologies?
Executive Summary
Introduction
Trends in cancer diagnostics
Market developments
Market analysis
About the author
Disclaimer
Introduction
Summary
Perspective
Growing global incidence of cancer
The impact of unhealthy lifestyles on cancer
Personalized therapy gets closer
Molecularly targeted therapeutics
Move toward rationally designed trials
Accelerate the translation of preclinical research
Strategies toward personal cancer treatment
Near-term market opportunities
New pharmacogenomics, panels and arrays
Driving demand for tests
Drug-diagnostic co-development
Targeted drugs fueling diagnostic growth
Stratifying patients to the best treatment
Trends in cancer diagnostics
Summary
An evolving science
Demonstrating value
Evolving health care practices
Reducing time to market
Addressing regulatory concerns
Changing clinical practice
Diagnostic influences therapeutic molecule discovery
Identifying patient populations
Key platforms
PCR
Nucleic acid testing
Microfluidics
Gene expression profiling
Variety
The role of biomarkers
Prognostic
Predictive
Evaluating therapeutic activity
Challenges and issues
Commercializing theranostics
Regulatory challenges
Technical challenges
DTCs and CTCs
Market developments
Summary
New molecular test for cervical cancer
Detecting high risk types of HPV
License for EGFR lung cancer assay
Licensing agreement extended for prostate cancer biomarker
bioMérieux, GSK develop theranostic for treatment selection
Diagnostic test for pancreatic cancer
Test to select candidates for skin cancer immunotherapy
Collaboration for therapy, companion diagnostic
Companion diagnostics collaboration
Deal to accelerate development of new cancer diagnosis tools
Biomarkers for personalizing radiation cancer treatment
CTC antibodies on a chip track mesothelioma
Body fluid based oncology diagnostics
Highly validated genetic markers for malignant melanoma
Biomarkers for DNA methylation on melanoma tissue
Diagnostic predicts prostate cancer recurrence
Colorectal cancer test approved
Market analysis
Summary
Market drivers
Improving on prescription by trial and error
A need for more rapid, specific testing
Opportunities
Drug-diagnostic combinations
Rescuing failed drugs
An unmet need for improving diagnosis
Selected novel products on the market
HPV and cervical cancer
Multigene expression testing
Predicting risk of recurrence
Gene overexpression
KRAS mutations
Molecular classification
Mutation analysis
Drug resistance testing
Measuring exposure to drugs
World market analysis
Total solutions
Drug labeling modifications
Breast cancer
Colorectal cancer
Prostate cancer
Non-small cell lung cancer
Melanoma
Renal cancer
Market by type of diagnostic
Corporate Profiles
Abbott Molecular
Company description
Agendia
Company description
Allegro Diagnostics
Company description
Almac Group
Company description
AltheaDx
Company description
Asuragen
Company description
Atossa Genetics
Company description
AutoGenomics
Company description
Becton, Dickinson and Company
Company description
Biocartis SA
Company description
bioMérieux SA
Company description
Caris Life Sciences
Company description
CCC Diagnostics LLC
Company description
Cytocell Ltd.
Company description
Dako Denmark
Company description
deCODE genetics
Company description
Epigenomics AG
Company description
Exosome Diagnostics
Company description
Foundation Medicine
Company description
GE Healthcare
Company description
Gene Express
Company description
Genomic Health
Company description
Gen-Probe
Company description
Illumina
Company description
IncellDx
Company description
Innogenetics NV
Company description
InterGenetics
Company description
Ipsogen
Company description
Kreatech Diagnostics
Company description
MDxHealth
Company description
Myriad Genetics
Company description
Nanosphere
Company description
Oncohealth
Company description
On-Q-ity
Company description
Orion Genomics
Company description
Pathwork Diagnostics
Company description
Predictive Biosciences
Company description
Prometheus Laboratories
Company description
Qiagen
Company description
QuantaLife
Company description
Roche Molecular Diagnostics
Company description
Rosetta Genomics
Company description
Transgene
Company description
TrimGen
Company description
TrovaGene
Company description
Veridex
Company description
Appendix
Scope
Methodology
Glossary/Abbreviations
Bibliography/References
To order this report:
In Vitro Diagnostic Industry: Advancing Molecular Diagnostics to Personalize Cancer Therapy
In Vitro Diagnostic Business News
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article